Registry following teenagers with atopic dermatitis under dermatology care
Collects long-term information on how atopic dermatitis treatments are used in adolescents.
Plain-language title generated from the registry record
Registry title: CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
Key facts
- Where
- Waltham, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 15 years old?
Source: NCT06238765, who can take part
Where in United States
- CorEvitas, LLCWaltham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorEvitas
- Trial code
- NCT06238765
- Record updated
- 29 June 2026
- Original description
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.Read full original descriptionShow less
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Inclusion: To be eligible to participate in this registry, an individual must meet all the following criteria:; Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare provider; Is 10 - 15 years of age at the time of enrollment; Subject has initiated or is initiating an enrollment-eligible medication at the time of enrollment.
Exclusion: An individual who meets any of the following criteria will be excluded from participation in the registry:; Is participating or planning to participate in a blinded clinical trial for an AD drug; Is unwilling or unable to provide standing height measurements.